Bio-Techne Corporation
NASDAQ:TECHBiotechnology
-$1.03 today
- Market cap
- $11.43B
- Beta
- 1.36
- P/E (TTM)
- 78.3
- EPS (TTM)
- $0.70
- Dividend yield
- 0.58%
Volume 2.63M
Average 2.66M
TECH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Bio-Techne CorporationNASDAQ: TECH
Research & Development · Q1 FY2027 · quarter ended Sep 2026
Research & development growth accelerates
Q1 FY2027 research & development of $26.34M rose 8.7% year over year, ahead of the -3.0% change in trailing-twelve-month research & development. Sequentially, it rose 10.0% from the prior quarter. Over 3 fiscal years it compounded at +0.8% a year.
Context
- Research & development amounted to 7.8% of revenue in FY2026, down 0.4 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +8.7% holds above the trailing-twelve-month pace of -3.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 94.77M USD
- Year-over-year change
- -4.8%
- 4-year CAGR
- +2.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 94.77M | -4.8% |
| FY2025 | 2025-06-30 | 99.5M | +2.9% |
| FY2024 | 2024-06-30 | 96.66M | +4.5% |
| FY2023 | 2023-06-30 | 92.49M | +6.1% |
| FY2022 | 2022-06-30 | 87.14M | — |
Research & Development vs competitors
How TECH compares with its peers on the latest reported figures
- TECH's LTM Sep 2026 research & development of $96.87M is the 9th highest of the 11 companies compared; the peer median is $241.82M.
- Its year-over-year change of -3.0% is the 7th highest of 10, against a peer median of -0.7%.
- Research & development amounts to 7.9% of revenue for TECH, versus a peer median of 9.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.67B | +4.2% | +1.5% | 6.5% | |
| LTM Sep 2026 | $1.41B | -0.7% | -1.7% | 3.0% | |
| LTM Jul 2026 | $485M | +8.5% | -0.9% | 6.6% | |
| LTM Jun 2026 | $393.5M | -1.6% | +18.8% | 11.2% | |
| LTM Jun 2026 | $261.1M | -14.3% | +0.0% | 10.1% | |
| LTM Sep 2026 | $222.54M | -10.9% | -3.5% | 36.0% | |
| LTM Jul 2026 | $215.83M | +5.2% | -0.9% | 7.4% | |
| LTM Jun 2026 | $194.67M | +5.5% | -0.4% | 9.3% | |
| LTM Sep 2026 | $96.87M | -3.0% | +0.8% | 7.9% | |
| LTM Mar 2026 | $41.33M | -11.2% | -6.2% | 274.8% | |
ALMRAlamar Biosciences, Inc. | FY2025 | $37.47M | — | — | 50.5% |
| Peer median (excluding TECH) | $241.82M | -0.7% | -0.9% | 9.7% | |
Competitors are the stored peer set for TECH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 1.11B | 1.14B | 1.16B | 1.22B | 1.22B |
| Cost of Revenue | 349.1M | 366.89M | 389.34M | 429.36M | 415.97M |
| Gross Profit | 756.5M | 769.82M | 769.73M | 790.27M | 799.07M |
| Gross Margin | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% |
| Research & Development | 87.14M | 92.49M | 96.66M | 99.5M | 94.77M |
| Selling, General & Admin | 339M | 352.44M | 393.32M | 415.1M | 452.42M |
| Operating Expenses | 459.91M | 470.87M | 563.04M | 688.02M | 547.18M |
| Depreciation & Amortization | 101.07M | 107.24M | 111.71M | 109.9M | 97.36M |
| EBITDA | 413.76M | 457.11M | 313.14M | 216.88M | 343.44M |
| EBITDA Margin | 37.4% | 40.2% | 27.0% | 17.8% | 28.3% |
| Operating Income | 296.59M | 298.94M | 206.69M | 102.26M | 251.89M |
| Operating Margin | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Interest Income | 794K | 3.41M | 3.32M | 3.89M | 0 |
| Interest Expense | 11.31M | 11.22M | 15.74M | 8.51M | 5.41M |
| Other Income / Expenses | 4.8M | 39.72M | (21M) | (3.79M) | (11.21M) |
| Income Before Tax | 301.39M | 338.66M | 185.69M | 98.46M | 240.68M |
| Pre-Tax Margin | 27.3% | 29.8% | 16.0% | 8.1% | 19.8% |
| Income Tax Expense | 38.29M | 53.22M | 17.58M | 25.06M | 58.82M |
| Net Income | 272.05M | 285.26M | 168.11M | 73.4M | 181.86M |
| Net Margin | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
| EPS (Basic) | 1.73 | 1.81 | 1.07 | 0.47 | 1.17 |
| EPS (Diluted) | 1.66 | 1.76 | 1.05 | 0.46 | 1.16 |
| Weighted Avg Shares | 156.88M | 157.18M | 157.71M | 157.52M | 155.96M |
| Weighted Avg Shares (Diluted) | 164.12M | 161.86M | 160.77M | 159.72M | 157.01M |
Bio-Techne Corporation
NASDAQ:TECH
Intrinsic Alpha fair value
Locked
Current Price
$72.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.